Lurbinectedin
Small-cell Lung Cancer
Sichuan UniversitySmall moleculePhase 3Active
BBB
72/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 67/ 100
- Competitive Position
- 81/ 100
Competitive context
24 Active assets in the Small-cell Lung Cancer cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Cyclophosphamide National Cancer Institute (NCI) | Phase 3 | BB |
(+)-VINCRISTINE PharmaMar | Phase 3 | B |
ql1604 Qilu Pharmaceutical Co., Ltd. | Phase 3 | B |
AMRUBICIN Sumitomo Pharma Co., Ltd. | Phase 3 | B |
Abemaciclib Case Comprehensive Cancer Center | Phase 2 | B |
View all 47 →
Same molecule, other indications
Lurbinectedin is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →